RU2019117562A - Соединения и их фармацевтические композиции для лечения воспалительных заболеваний - Google Patents

Соединения и их фармацевтические композиции для лечения воспалительных заболеваний Download PDF

Info

Publication number
RU2019117562A
RU2019117562A RU2019117562A RU2019117562A RU2019117562A RU 2019117562 A RU2019117562 A RU 2019117562A RU 2019117562 A RU2019117562 A RU 2019117562A RU 2019117562 A RU2019117562 A RU 2019117562A RU 2019117562 A RU2019117562 A RU 2019117562A
Authority
RU
Russia
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
subject
sarcoidosis
Prior art date
Application number
RU2019117562A
Other languages
English (en)
Russian (ru)
Other versions
RU2019117562A3 (cg-RX-API-DMAC7.html
Inventor
Шанталь Терез ТАССЕ
Пилл ГАРРИСОН
Рене Александр ГАЛЬЕН
Джон Сарджент САНДИ
Джон Г. МАКХАТЧИСОН
Томас О'РАЙОРДЕН
Нилуфар МОЗЕФФАРИАН
Уптал Динеш ПАТЕЛ
Тимоти Р. УОТКИНС
Дэвид Л. ГОССЕЙДЖ
Original Assignee
Галапагос Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Галапагос Нв filed Critical Галапагос Нв
Publication of RU2019117562A publication Critical patent/RU2019117562A/ru
Publication of RU2019117562A3 publication Critical patent/RU2019117562A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2019117562A 2016-11-10 2017-11-09 Соединения и их фармацевтические композиции для лечения воспалительных заболеваний RU2019117562A (ru)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB201618959 2016-11-10
GB201618962 2016-11-10
GB201618963 2016-11-10
GB1618959.9 2016-11-10
GB1618962.3 2016-11-10
GB1618963.1 2016-11-10
GB1618961.5 2016-11-10
GB1618960.7 2016-11-10
GB1618964.9 2016-11-10
GB201618961 2016-11-10
GB201618964 2016-11-10
GB201618960 2016-11-10
PCT/EP2017/078701 WO2018087202A1 (en) 2016-11-10 2017-11-09 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases

Publications (2)

Publication Number Publication Date
RU2019117562A true RU2019117562A (ru) 2020-12-10
RU2019117562A3 RU2019117562A3 (cg-RX-API-DMAC7.html) 2021-02-09

Family

ID=60388032

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019117562A RU2019117562A (ru) 2016-11-10 2017-11-09 Соединения и их фармацевтические композиции для лечения воспалительных заболеваний

Country Status (8)

Country Link
US (1) US20190314382A1 (cg-RX-API-DMAC7.html)
EP (1) EP3538103A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019534304A (cg-RX-API-DMAC7.html)
AU (1) AU2017358703A1 (cg-RX-API-DMAC7.html)
CA (1) CA3043396A1 (cg-RX-API-DMAC7.html)
RU (1) RU2019117562A (cg-RX-API-DMAC7.html)
TW (1) TW201821080A (cg-RX-API-DMAC7.html)
WO (1) WO2018087202A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019132654A1 (en) * 2017-12-27 2019-07-04 Erasmus University Medical Center Rotterdam Methods of treating sarcoidosis
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2020009566A1 (en) * 2018-07-04 2020-01-09 Erasmus University Medical Center Rotterdam Methods of treating sarcoidosis
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
US11602536B2 (en) 2019-06-10 2023-03-14 Incyte Corporation Topical treatment of vitiligo by a JAK inhibitor
JP7518900B2 (ja) * 2019-10-16 2024-07-18 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN115282168B (zh) * 2022-08-30 2024-05-31 马应龙大健康有限公司 一种缓解婴幼儿湿疹症状的舒缓润肤霜及其制备方法和应用
CN119157881A (zh) * 2024-09-25 2024-12-20 Jje有限公司 Jak2抑制剂在制备治疗慢性肾脏病的药物中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070111956A1 (en) 2003-07-03 2007-05-17 Japan Science And Technology Agency Remedy for sarcoidosis and method of treating the same
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
DK2830662T3 (da) * 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
MX368511B (es) 2012-06-22 2019-10-07 Galapagos Nv Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma.
EP3060234A1 (en) * 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
SMT202300328T1 (it) 2015-04-13 2023-11-13 Galapagos Nv Metodi per il trattamento di disturbi cardiovascolari
KR20170134750A (ko) 2015-04-13 2017-12-06 갈라파고스 엔.브이. 염증 질환의 치료 방법
AU2016259023A1 (en) * 2015-05-07 2017-11-30 The Trustees Of Columbia University In The City Of New York Methods and compositions for promoting hair growth

Also Published As

Publication number Publication date
EP3538103A1 (en) 2019-09-18
TW201821080A (zh) 2018-06-16
JP2019534304A (ja) 2019-11-28
WO2018087202A1 (en) 2018-05-17
AU2017358703A1 (en) 2019-05-09
US20190314382A1 (en) 2019-10-17
RU2019117562A3 (cg-RX-API-DMAC7.html) 2021-02-09
CA3043396A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
JP2019534304A5 (cg-RX-API-DMAC7.html)
JP2020526483A5 (cg-RX-API-DMAC7.html)
JP2023528804A5 (cg-RX-API-DMAC7.html)
Daniels et al. Is the Parkland formula still the best method for determining the fluid resuscitation volume in adults for the first 24 hours after injury?—A retrospective analysis of burn patients in Germany
Memme et al. Activating transcription factor 4 regulates mitochondrial content, morphology, and function in differentiating skeletal muscle myotubes
Polyák et al. Long-term endurance training-induced cardiac adaptation in new rabbit and dog animal models of the human athlete’s heart
AU2016276488A1 (en) Use of composition for preparing a medicament for treatment of amyotrophic lateral sclerosis
WO2014134569A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis in responders
KR20160079899A (ko) 신경퇴행성 질환 또는 인지 결핍을 치료하기 위한 인돌릴 및 이돌리닐 하이드록사메이트의 용도
ES2575676T3 (es) Composición de colirio
Shimojima et al. Ten-year follow-up of peripheral nerve function in patients with familial amyloid polyneuropathy after liver transplantation
Cavalcanti et al. Low‐intensity treadmill exercise‐related changes in the rat stellate ganglion neurons
RU2013156363A (ru) Диагностика инфекционного заболевания дыхательных путей с использованием образцов крови
CN115175682A (zh) 使用布鲁顿氏酪氨酸激酶的抑制剂治疗原发进展型多发性硬化症的方法
WO2025098219A1 (zh) 川芎嗪硝酮衍生物在制备预防或治疗肌少症药物中的应用
Tourette et al. Biophytis BIO101 in sarcopenia: Update on the SARA program: From SARA-INT towards the phase 3 study
Alla et al. Clinical profiles of elderly patients presenting with persistent dizziness
Gandar et al. In vitro and in vivo assessment of eprociclovir as antiviral treatment against testudinid herpesvirus 3 in Hermann's tortoise (Testudo hermanni)
US10806739B2 (en) Use of n-desmethylclobazam in the treatment of chronic pain disorders and related methods
Suzuki et al. Dose-dependent increase in the QTc interval in aripiprazole treatment after risperidone.
Villanueva et al. Effect of first-pass hepatic metabolism on the disposition of levamisole after intravenous administration in rabbits
Seada et al. Implication changes of serum adiponectin in chronic Moderate aerobic and resistant pattern of exercise in male albino rat model of Alzheimer
Derakhchan et al. Evaluation of cardiac conduction disturbances using jacketed external telemetry (JET) in conscious non-human primates (NHP)
Acosta Viana et al. Effectiveness of Intralesional Triamcinolone in the Treatment of Keloids in Children
HK40082153A (en) Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton’s tyrosine kinase

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20210804